Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to...
